Neutralization capacity of convalescent plasma against SARS-CoV-2 omicron sublineages: Implications for donor selection

Vox Sang. 2023 Dec;118(12):1145-1147. doi: 10.1111/vox.13539. Epub 2023 Oct 10.

Authors

Reuben McGregor¹, Lauren Carlton¹, Aimee Paterson¹, Thomas Hills^{2

3}, Richard Charlewood^{1

4}, Nicole J Moreland¹

Affiliations

¹ Department of Molecular Medicine and Pathology, School of Medical Sciences, The University of Auckland, Auckland, New Zealand.
² Te Toka Tumai Auckland, Te Whatu Ora (Health New Zealand), Auckland, New Zealand.
³ Medical Research Institute of New Zealand, Wellington, New Zealand.
⁴ New Zealand Blood Service, Auckland, New Zealand.

PMID: 37817295
DOI: 10.1111/vox.13539

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Neutralizing / therapeutic use
Antibodies, Viral / therapeutic use
COVID-19 Serotherapy
COVID-19* / therapy
Cell Differentiation
Donor Selection*
Humans
Neutralization Tests
SARS-CoV-2

Substances

Antibodies, Viral
Antibodies, Neutralizing